Loading clinical trials...

Amobarbital and Cardiopulmonary Bypass | Clinical Trials | Clareo Health

RECRUITINGNA

Amobarbital and Cardiopulmonary Bypass

The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

NCT06757868•Tongji Hospital

View on ClinicalTrials.gov

Summary

Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Detailed Description

AMO is a short acting complex I blocker that blocks mitochondrial complex I between flavoprotein and ubiquitin, and its blocking effect can be rapidly reversed. Our study is to explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation.
•ASA II-III;
•surgical duration is 3-6 hours;
•Sign the informed consent form

Exclusion Criteria

•BMI less than 18 kg/m2 or greater than 30 kg/m2;
•Individuals with a history or potential history of drug abuse or alcohol dependence;
•Preoperative use of sedatives or analgesics;
•Individuals with severe liver and kidney dysfunction;
•Individuals who are allergic or potentially allergic to barbiturates;
•Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status;
•Participated in other clinical studies in the past 3 months;
•The researchers believe that participants who are not suitable to participate in this study.

Locations (1)

Tongji hospital

Wuhan, Hubei, China

Key Dates

Start Date

February 1, 2025

Primary Completion Date

December 31, 2025

Completion Date

March 1, 2026

Last Updated

March 21, 2025

Enrollment

ESTIMATED participants

Conditions

Cardiopulmonary Bypass

Interventions

Amobarbital

DRUG

Midazolam

DRUG

Contacts

mujun chang, Dr

CONTACT

+862783663625 changmujun@hotmail.com

Pu zhou, Dr

CONTACT

+862783663625 tongjihlunli@163.com

Ultrasound Guided Bilateral Pectoral Nerve Block Versus Bilateral Transverse Thoracic Plane Block In Pediatric Patients Undergoing Corrective Cardiac Surgeries Requiring Cardiopulmonary Bypass Via Median Sternotomy

NCT06984276

UltrasoundPectoral Nerve Block+5 more

View study

RECRUITINGNA

Effect of Low Tidal Volume Ventilation on Postoperative Delirium

NCT06752421

Postoperative Delirium (POD)Cardiopulmonary Bypass+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Amobarbital and Cardiopulmonary Bypass

Inclusion Criteria

Exclusion Criteria

Ultrasound Guided Bilateral Pectoral Nerve Block Versus Bilateral Transverse Thoracic Plane Block In Pediatric Patients Undergoing Corrective Cardiac Surgeries Requiring Cardiopulmonary Bypass Via Median Sternotomy

Effect of Low Tidal Volume Ventilation on Postoperative Delirium

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery

Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)

Influence of Lung Volume Optimization Maneuver in Ventilated Children on Cardiac Output and Lung Compliance in Children With Congenital Heart Disease Undergoing Surgical Repair

Cardioplegic Protection of the Heart